Prognostic factors in patients with advanced cholangiocarcinoma: Role of surgery, chemotherapy and body mass index

Mirna H. Farhat, Ali I. Shamseddine, Ayman N. Tawil, Ghina Berjawi, Charif Sidani, Wael Shamseddeen, Kassem A. Barada

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Aim: To study the factors that may affect survival of cholangiocarcinoma in Lebanon. Methods: A retrospective review of the medical records of 55 patients diagnosed with cholangiocarcinoma at the American University of Beirut between 1990 and 2005 was conducted. Univariate and multivariate analyses were performed to determine the impact of surgery, chemotherapy, body mass index, bilirubin level and other factors on survival. Results: The median survival of all patients was 8.57 mo (0.03-105.2). Univariate analysis showed that low bilirubin level (< 10 mg/dL), radical surgery and chemotherapy administration were significantly associated with better survival (P = 0.012, 0.038 and 0.038, respectively). In subgroup analysis on patients who had no surgery, chemotherapy administration prolonged median survival significantly (17.0 mo vs 3.5 mo, P = 0.001). Multivariate analysis identified only low bilirubin level < 10 mg/dL and chemotherapy administration as independent predictors associated with better survival (P < 0.05). Conclusion: Our data show that palliative and postoperative chemotherapy as well as a bilirubin level < 10 mg/dL are independent predictors of a significant increase in survival in patients with cholangiocarcinoma.

Original languageEnglish (US)
Pages (from-to)3224-3230
Number of pages7
JournalWorld Journal of Gastroenterology
Volume14
Issue number20
DOIs
StatePublished - May 28 2008
Externally publishedYes

Keywords

  • Biliary tract cancer
  • Bilirubin
  • Chemotherapy
  • Cholangiocarcinoma
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Prognostic factors in patients with advanced cholangiocarcinoma: Role of surgery, chemotherapy and body mass index'. Together they form a unique fingerprint.

Cite this